Nootropics Ropinirole Hydrochloride Pharmaceutical from buzai232's blog

Nootropics Ropinirole Hydrochloride Pharmaceutical powder for Parkinson′s Disease Product Name: 4-(2-Di-n-propylaminoethyl)-1,3-dichloro-2H-indol-2-one hydrochloride CAS: 91374-20-8 Standard: Enterprise Standard Natural / synthetic: synthetic Level: Pharmaceutical grade Content: 99% Appearance: white crystal Packing: 25KG/ cardboard drum Area: Early idiopathic Parkinson's disease Deferred product: Parkinson's drug Application: Acting on postsynaptic receptors in the striatum, compensating for the deficiency of dopamine, and compensating for increased sympathetic tone. Ropinirole can also be used for adjuvant treatment of patients who have already had switching problems. It can directly act on synaptic receptors, and it can produce continuous stimulation, thus alleviating the movement fluctuation of L-dopa, reducing its movement difficulty and reducing the dosage.Best Nootropics powder Nootropics Ropinirole Hydrochloride Pharmaceutical powder for Parkinson's Disease Description: Ropinirole has some of the same effects as a chemical called dopamine, which occurs naturally in your body. Low levels of dopamine in the brain are associated with Parkinson's disease. Ropinirole is used to treat symptoms of Parkinson's disease (stiffness, tremors, muscle spasms, and poor muscle control). Ropinirole is also used to treat restless legs syndrome (RLS). Only immediate-release ropinirole (Requip) is approved to treat either Parkinson symptoms or RLS. Extended-release ropinirole (Requip XL) is approved only to treat Parkinson symptoms. Parkinson's and RLS are two separate disorders. Having one of these conditions will not cause you to have the other condition.Nootropics Ropinirole Hydrochloride Pharmaceutical powder for Parkinson's Disease Dosage: The recommended starting dose for Parkinson's disease is 0.25 mg three times daily. Based on individual patient therapeutic response and tolerability, if necessary, the dose should then be titrated with weekly increments as described in Table 1. After Week 4, if necessary, the daily dose may be increased by 1.5 mg/day on a weekly basis up to a dose of 9 mg/day, and then by up to 3 mg/day weekly up to a maximum recommended total daily dose of 24 mg/day (8 mg three times daily). Doses greater than 24 mg/day have not been tested in clinical trials.